Start Date
April 16, 2021
Primary Completion Date
June 10, 2024
Study Completion Date
June 9, 2025
Sargramostim (GM-CSF)
Drug that binds to the protein PD-1 to help immune cells kill cancer cells better, it is given as an intravenous injection through a vein.
Pembrolizumab (anti-PD-1)
Drug that stimulates blood cells that may help support the immune system during cancer treatment, given as intravenous infusion
Collaborators (1)
Partner Therapeutics (PTx)
UNKNOWN
Dana-Farber Cancer Institute
OTHER